SRPT
Sarepta Therapeutics
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: SRPT
- PE Ratio
As of Jun 23, 2026, the Sarepta Therapeutics stock's PE ratio is 28.77. This results from the current EPS of $0.6 and stock price of $17.26.
SRPT PE ratio history
The PE ratio of Sarepta Therapeutics has averaged 138.4 over the last three years. The current PE ratio of 28.77 is 79% below the historical average. Over the past three years, SRPT's PE ratio was at its highest in the Mar 2024 quarter at 315.76, when the stock price was $129.46 and the EPS was $0.41. The lowest value was in the Mar 2026 quarter, when it reached 36.27 with a price of $21.76 and an EPS of $0.6.
Sarepta Therapeutics PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $21.52 | -$7.13 |
| 2024 | 49.23 | N/A | $121.59 | $2.47 |
| 2023 | N/A | N/A | $96.43 | -$5.8 |
| 2022 | N/A | N/A | $129.58 | -$8.03 |
| 2021 | N/A | N/A | $90.05 | -$5.15 |
| 2020 | N/A | N/A | $170.49 | -$7.11 |
| 2019 | N/A | N/A | $129.04 | -$9.71 |
| 2018 | N/A | N/A | $109.13 | -$5.46 |
| 2017 | N/A | N/A | $55.64 | -$0.86 |
| 2016 | N/A | N/A | $27.43 | -$5.49 |
| 2015 | N/A | N/A | $38.58 | -$5.2 |
| 2014 | N/A | N/A | $14.47 | -$3.39 |
| 2013 | N/A | N/A | $20.37 | -$3.31 |
| 2012 | N/A | N/A | $25.8 | -$5.14 |
| 2011 | N/A | N/A | $4.47 | -$0.11 |
Sarepta Therapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 36.27 | N/A | $21.76 | $0.6 |
| Dec 2025 | N/A | N/A | $21.52 | -$7.13 |
| Sep 2025 | N/A | N/A | $19.27 | -$2.72 |
| Jun 2025 | N/A | N/A | $17.1 | -$0.57 |
| Mar 2025 | N/A | N/A | $63.82 | -$2.51 |
| Dec 2024 | 49.23 | -38.51% | $121.59 | $2.47 |
| Sep 2024 | 80.06 | -62% | $124.89 | $1.56 |
| Jun 2024 | 210.67 | -33.28% | $158 | $0.75 |
| Mar 2024 | 315.76 | N/A | $129.46 | $0.41 |
| Dec 2023 | N/A | N/A | $96.43 | -$5.8 |
| Sep 2023 | N/A | N/A | $121.22 | -$7.83 |
| Jun 2023 | N/A | N/A | $114.52 | -$10.31 |
| Mar 2023 | N/A | N/A | $137.83 | -$12.69 |
| Dec 2022 | N/A | N/A | $129.58 | -$8.03 |
| Sep 2022 | N/A | N/A | $110.54 | -$8.22 |
SRPT Price vs fair value
SRPT average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, SRPT's PE ratio is below the 3, 5 and 10-year averages.
PE comparison
Sarepta Therapeutics's P/E of 28.77 is above the Healthcare sector and the industry average. Compared to its Healthcare sector average of 23.78, Sarepta Therapeutics's P/E is 21% higher.
SRPT PE vs peers
Compared to its peer ALNY, SRPT's PE ratio stands lower, however it is higher than GILD's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| GILD Gilead Sciences Inc | 16.85 | $155.26B |
| SRPT Sarepta Therapeutics Inc | 28.77 | $1.82B |
| ALNY Alnylam Pharmaceuticals Inc | 66.1 | $38.48B |
| NVAX Novavax Inc | N/A | $1.48B |
| PTCT Ptc Therapeutics Inc | N/A | $6.81B |
| BCRX Biocryst Pharmaceuticals Inc | N/A | $2.37B |
| INSM INSMED Inc | N/A | $22.14B |
Frequently asked questions
What is Sarepta Therapeutics's PE ratio?
The price to earnings ratio for SRPT stock is 28.77 as of Jun 23, 2026.
What is the 3-year average PE ratio for Sarepta Therapeutics (SRPT)?
The average PE ratio for SRPT stock over the past 3 years is 138.4.
What is the 5-year average PE ratio for Sarepta Therapeutics (SRPT)?
The average PE ratio for SRPT stock over the past 5 years is 138.4.
What is the highest PE ratio for SRPT?
The highest quarterly PE ratio in the last three years has been 315.76 and it was in the Mar 2024 quarter.
How does the current PE ratio for SRPT compare to its historical average?
SRPT's price to earnings ratio is currently 79% below its 3-year historical average.
How is SRPT's PE ratio calculated (Sarepta Therapeutics PE ratio formula)?
You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Jun 23, 2026), Sarepta Therapeutics's stock price is $17.26. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.6. Therefore, Sarepta Therapeutics's P/E ratio for today is 28.77. PE RATIO(28.77) = STOCK PRICE($17.26) / TTM EPS($0.6)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.